RG 2077

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameRG 2077
Drug Alias NameRG1046CTLA4-Ig - RepligenCTLA4-IG4mRG2077
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsCluster of differentiation 80 inhibitors
TargetsCluster of differentiation 80Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus NephritisMultiple Sclerosis, Relapsing-Remitting +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRepligen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, SystemicLupus NephritisMultiple Sclerosis, Relapsing-Remitting +[4] 

Other Information

ATC CodeN/A
Related LinksN/A